Holmes Biopharma Appoints Associate Director of Clinical Operations

Holmes Biopharma, Inc. (PINK SHEETS: HLMB) is pleased to welcome Mark Slama as Associate Director of Clinical Operations for Qualia Clinical Services.

Mark holds a Bachelor of Arts from Concordia University, Nebraska and adds over 17 years of industry experience to Qualia and Holmes Biopharma's Management Team. Prior to joining Qualia, he had fulfilled several roles at MDS Pharma Services, a global clinical research company with over 4,000 employees. His vast experience includes such positions as, Clinical Science Manager, Clinical Research Associate, Study Coordinator and QC Technician.

"As Qualia continues to focus on developing a global presence, the addition of Mark to our Clinical Operations team provides significant industry experience further taking our Omaha operation to the next level of success," said Mr. John F. Metcalfe, President and CEO.

About Holmes:

Holmes Biopharma, Inc. and its wholly owned subsidiary, Qualia Clinical Services, Inc. is a contract research organization focused on providing integrated and cost effective clinical development services that help the pharmaceutical industry introduce new drug products rapidly from laboratory to the market. It currently has clinics in Omaha, Nebraska and Toronto, Canada. For more information about the company please visit our website at www.holmesbiopharma.com.

On behalf of the Board of Directors

John F. Metcalfe, President

Certain statements in this press release constitute "forward looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.